Haemonetics Corporation (HAE)

Cash ratio

		Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020
Cash and cash equivalents	US$ in thousands	306,763	320,846	299,283	344,429	178,800	193,978	351,005	285,719	284,466	224,002	241,200	214,948	259,496	236,877	192,420	173,462	192,305	189,002	279,169	275,725
Short-term investments	US$ in thousands	—	—	—	1,636	1,673	1,146	2,576	2,442	1,110	1,687	1,114	—	—	—	—	—	—	—	—	—
Total current liabilities	US$ in thousands	578,113	253,233	273,946	260,076	300,383	261,755	264,215	236,939	251,816	226,889	262,175	180,487	442,266	355,411	288,470	228,339	253,495	194,384	338,568	407,827
Cash ratio		0.53	1.27	1.09	1.33	0.60	0.75	1.34	1.22	1.13	0.99	0.92	1.19	0.59	0.67	0.67	0.76	0.76	0.97	0.82	0.68

March 31, 2025 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($306,763K + $—K) ÷ $578,113K
= 0.53

The cash ratio of Haemonetics Corporation has fluctuated over the past few years, ranging from a low of 0.53 as of March 31, 2025, to a high of 1.34 as of September 30, 2023. The cash ratio measures the company's ability to cover its current liabilities with its cash and cash equivalents. A higher cash ratio indicates a stronger ability to cover short-term obligations.

During the period under review, the company's cash ratio generally stayed above 1.0, except for a few quarters where it dipped below that level. This suggests that Haemonetics Corporation has generally maintained a healthy level of cash reserves relative to its current liabilities, indicating a lower risk of liquidity issues.

It is important for investors and analysts to monitor the cash ratio over time to assess the company's liquidity position and its ability to meet short-term financial obligations. fluctuations in the cash ratio could be influenced by factors such as changes in cash holdings, variations in current liabilities, or shifts in operating performance.

Overall, Haemonetics Corporation's cash ratio trends reflect a company that has managed its liquidity reasonably well, but continued monitoring is essential to ensure sustainable financial health.